BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 10327061)

  • 21. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
    Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
    Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
    Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
    Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53AIP1 expression can be a prognostic marker in non-small cell lung cancer.
    Yamashita SI; Masuda Y; Yoshida N; Matsuzaki H; Kurizaki T; Haga Y; Ikei S; Miyawaki M; Kawano Y; Chujyo M; Kawahara K
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):148-51. PubMed ID: 17851056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
    Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR
    J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
    Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
    Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
    Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
    Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
    Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
    Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Establishment and evaluation of a prognostic prediction model for patients after complete resection of non-small cell lung cancer and multidisciplinary therapy].
    Wei WD; Fu JH; Lin P; Li XD; Yang H; Rong TH; Chen LK
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):672-5. PubMed ID: 19173908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
    Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
    Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.